Literature DB >> 18073348

Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia.

Emilie Le Toriellec1, Gilles Despouy, Gaëlle Pierron, Nogaye Gaye, Marjorie Joiner, Dorine Bellanger, Anne Vincent-Salomon, Marc-Henri Stern.   

Abstract

T-cell prolymphocytic leukemia (T-PLL) is consistently associated with inactivation of the ATM gene and chromosomal re-arrangements leading to an overexpression of MTCP1/TCL1 oncoproteins. These alterations are present at the earliest stage of malignant transformation, suggesting that additional events are required for overt malignancy. In this study, we pursued the investigation of the 12p13 deletion, previously shown to occur in approximately half of T-PLLs. We refined the minimal region of deletion by single nucleotide and microsatellite polymorphism allelotyping. We defined a 216-kb region containing the CDKN1B gene that encodes the cyclin-dependent kinase inhibitory protein p27(KIP1). Sequencing this gene in 47 T-PLL patient samples revealed a nonsense mutation in one case without 12p13 deletion. The absence of biallelic inactivation of CDKN1B for most patients suggested a haploinsufficiency mechanism for tumor suppression, which was investigated in an animal model of the disease. In a Cdkn1b(+/-) background, MTCP1 transgenics had consistent and multiple emergences of preleukemic clones not observed in control cohorts. The second Cdkn1b allele was maintained and expressed in these preleukemic clones. Altogether, these data strongly implicate CDKN1B haploinsufficiency in the pathogenesis of T-PLL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18073348     DOI: 10.1182/blood-2007-06-095570

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy.

Authors:  Daniel Nowak; Emilie Le Toriellec; Marc-Henri Stern; Norihiko Kawamata; Tadayuki Akagi; Martin J Dyer; Wolf-Karsten Hofmann; Seishi Ogawa; H Phillip Koeffler
Journal:  Haematologica       Date:  2009-03-10       Impact factor: 9.941

2.  Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways.

Authors:  Akihiko Yokoyama; Francesca Ficara; Mark J Murphy; Christian Meisel; Alpana Naresh; Issay Kitabayashi; Michael L Cleary
Journal:  J Cell Sci       Date:  2011-07-01       Impact factor: 5.285

3.  Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Authors:  E I Andersson; S Pützer; B Yadav; O Dufva; S Khan; L He; L Sellner; A Schrader; G Crispatzu; M Oleś; H Zhang; S Adnan-Awad; S Lagström; D Bellanger; J P Mpindi; S Eldfors; T Pemovska; P Pietarinen; A Lauhio; K Tomska; C Cuesta-Mateos; E Faber; S Koschmieder; T H Brümmendorf; S Kytölä; E-R Savolainen; T Siitonen; P Ellonen; O Kallioniemi; K Wennerberg; W Ding; M-H Stern; W Huber; S Anders; J Tang; T Aittokallio; T Zenz; M Herling; S Mustjoki
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

4.  Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.

Authors:  Zainul S Hasanali; Bikramajit Singh Saroya; August Stuart; Sara Shimko; Juanita Evans; Mithun Vinod Shah; Kamal Sharma; Violetta V Leshchenko; Samir Parekh; Thomas P Loughran; Elliot M Epner
Journal:  Sci Transl Med       Date:  2015-06-24       Impact factor: 17.956

Review 5.  Solving the genetic puzzle of systemic lupus erythematosus.

Authors:  Wanling Yang; Yu Lung Lau
Journal:  Pediatr Nephrol       Date:  2014-09-20       Impact factor: 3.714

Review 6.  Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.

Authors:  Aude Collignon; Anne Wanquet; Elsa Maitre; Edouard Cornet; Xavier Troussard; Thérèse Aurran-Schleinitz
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

7.  Haploinsufficient tumor suppressor genes.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Adv Med Biol       Date:  2017 1st Quarter

8.  Cks1 is a critical regulator of hematopoietic stem cell quiescence and cycling, operating upstream of Cdk inhibitors.

Authors:  V Tomiatti; R Istvánffy; E Pietschmann; S Kratzat; A Hoellein; L Quintanilla-Fend; N von Bubnoff; C Peschel; R A J Oostendorp; U Keller
Journal:  Oncogene       Date:  2014-11-24       Impact factor: 9.867

9.  Hemizygosity for Atm and Brca1 influence the balance between cell transformation and apoptosis.

Authors:  Fengtao Su; Lubomir B Smilenov; Thomas Ludwig; Libin Zhou; Jiayun Zhu; Guangming Zhou; Eric J Hall
Journal:  Radiat Oncol       Date:  2010-02-22       Impact factor: 3.481

10.  Somatic alterations of CDKN1B are associated with small bowel neuroendocrine tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; Guiying Li; Allen B Choi; Andrew M Bellizzi; Thomas M O'Dorisio; James R Howe
Journal:  Cancer Genet       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.